0001209191-21-018407.txt : 20210305
0001209191-21-018407.hdr.sgml : 20210305
20210305194404
ACCESSION NUMBER: 0001209191-21-018407
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210303
FILED AS OF DATE: 20210305
DATE AS OF CHANGE: 20210305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Knowles Julius
CENTRAL INDEX KEY: 0001808365
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 21720305
MAIL ADDRESS:
STREET 1: C/O KEROS THERAPEUTICS, INC.
STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-513-8774
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-03
0
0001664710
Keros Therapeutics, Inc.
KROS
0001808365
Knowles Julius
C/O KEROS THERAPEUTICS, INC.
99 HAYDEN AVENUE, SUITE 120, BUILDING E
LEXINGTON
MA
02421
1
0
0
0
Common Stock
2021-03-03
4
S
0
793
55.91
D
643695
I
See footnote
Common Stock
2021-03-03
4
S
0
518
55.91
D
429765
I
See footnote
Common Stock
2021-03-03
4
S
0
3004
56.95
D
640691
I
See footnote
Common Stock
2021-03-03
4
S
0
1958
56.95
D
427807
I
See footnote
Common Stock
2021-03-03
4
S
0
2903
57.79
D
637788
I
See footnote
Common Stock
2021-03-03
4
S
0
1894
57.79
D
425913
I
See footnote
Common Stock
2021-03-03
4
S
0
761
58.88
D
637027
I
See footnote
Common Stock
2021-03-03
4
S
0
496
58.88
D
425417
I
See footnote
Common Stock
2021-03-04
4
S
0
1662
54.22
D
635365
I
See footnote
Common Stock
2021-03-04
4
S
0
1086
54.22
D
424331
I
See footnote
Common Stock
2021-03-04
4
S
0
2962
55.21
D
632403
I
See footnote
Common Stock
2021-03-04
4
S
0
1932
55.21
D
422399
I
See footnote
Common Stock
2021-03-04
4
S
0
1376
56.18
D
631027
I
See footnote
Common Stock
2021-03-04
4
S
0
895
56.18
D
421504
I
See footnote
Common Stock
2021-03-04
4
S
0
847
57.21
D
630180
I
See footnote
Common Stock
2021-03-04
4
S
0
553
57.21
D
420951
I
See footnote
Common Stock
2021-03-04
4
S
0
193
58.03
D
629987
I
See footnote
Common Stock
2021-03-04
4
S
0
126
58.03
D
420825
I
See footnote
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 to
$56.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in
footnotes (2), (5), (6), (7), (8), (9), (10), (11) and (12).
The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general
partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be
deemed to share voting and investment power with respect to the shares held by PIF I.
The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general
partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be
deemed to share voting and investment power with respect to the shares held by PIF II.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.41 to
$57.40 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.42 to
$58.38 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.46 to
$59.19 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.76 to $54.72 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.76 to $55.75 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.77 to $56.75 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.80 to $57.59 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.86 to $58.18 inclusive.
/s/ Keith Regnante, Attorney-in-Fact
2021-03-05